A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

NCT05562466 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: QMF149
DRUG: Budesonide

Sponsor

Novartis Pharmaceuticals